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Abstract
Background: The clinical treatment of various types of pain relies upon the use of opioid analgesics. However
most of them produce, in addition to the analgesic effect, several side effects such as the development of
dependence and addiction as well as sedation, dysphoria, and constipation. One solution to these problems are
chimeric compounds in which the opioid pharmacophore is hybridized with another type of compound to incease
antinociceptive effects. Neurotensin-induced antinociception is not mediated through the opioid system. Therefore,
hybridizing neurotensin with opioid elements may result in a potent synergistic antinociceptor.
Results: Using the known structure-activity relationships of neurotensin we have synthesized a new chimeric
opioid-neurotensin compound PK20 which is characterized by a very strong antinociceptive potency. The
observation that the opioid antagonist naltrexone did not completely reverse the antinociceptive effect, indicates
the partial involvement of the nonopioid component in PK20 in the produced analgesia.
Conclusions: The opioid-neurotensin hybrid analogue PK20, in which opioid and neurotensin pharmacophores
overlap partially, expresses high antinociceptive tail-flick effects after central as well as peripheral applications.
Background
The opioids system is the major endogenous pathway
that modulates pain signal transmission and perception.
Therefore most pain medicines, available for the treat-
ment of severe pain, express affinity for the opioid
receptors. The search for selective opioid compounds is
still a main avenue in the development of new analge-
sics. However, pain is mediated by various complemen-
tary and/or alternative pathways that participate in the
creation of a final level of pain perception. Therefore,
we have proposed a new, multitarget approach in
searching for new analgesics [1]. According to this con-
cept, the new type of analgesics should interact with a
broad spectrum of pathways involved in pain transmis-
sion and modulation. The use of a peptidomimetic in
the chemical structure of the drug allows to modulate
the permeability of the active substance and, in
consequence, creates “site specificity of action”.T h i s
concept has been positively proven with the creation of
multitarget molecules interacting with broad spectrum
of opioid receptors [2] or opioid and NK1-, [3,4] CCK-,
[5] or neurotensin receptors [6].
The tridecapeptide neurotensin, (NT, p-Glu
1-Leu
2-Tyr
3-
Glu
4-Asn
5-Lys
6-Pro
7-Arg
8-Arg
9-Pro
10-Tyr
11-Ile
12-Leu
13)
[7-10] exerts antinociceptive activity, and is therefore con-
sidered as a pain modulating factor [11]. Microinjection
experiments have provided evidence that NT can modu-
late pain transmission in several brain regions and path-
ways that are involved in the central integration of pain
responses, including the central amygdale, the hypothala-
mic medial preoptic nucleus (MPO), certain thalamic
nuclei, the periaqueductal gray (PAG), and the rostroven-
tral medulla (RVM) [11,12]. Interestingly, neurotensin has
bipolar (facilitatory and inhibitory) effects on pain modula-
tion, which depend on the injected doses. Facilitation pre-
dominates at low (picomolar) doses of NT injected into
the RVM, whereas higher doses (nanomolar) produce anti-
nociception [13]. Until now, the NTS1 and NTS2 receptor
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receptors, appear to be required for different aspects of
neurotensin-induced analgesia [11,14,15].
When administered intracerebroventricularly (i.c.v.),
NT induces a strong naloxone-insensitive analgesic
effect [16-18], suggesting that NT operates indepen-
dently of opioidergic transmission.
Structure-activity relationship studies with a number
of neurotensin analogs and partial sequences have estab-
lished that the C-terminal hexapeptide of NT contains
all the structural requirements for receptor binding and
activation.
Moreover, the introduction of altered amino acids,
relative to the native sequence, into the peptide, can
improve the metabolic stability [19-21] and have a cru-
cial influence on its function and activity [22,23]. In
contrast to NT, the N-terminal fragment is crucial for
the interaction of opioid peptides with all opioid recep-
tors. Sequence analysis of the active fragment of both
peptides resulted in the development of new analogues,
in which the active opioid and neurotensin fragments
partially overlap. Therefore, the final compounds should
express independent affinities to opioid and nociceptin
receptors [24]. The most potent compound of this ser-
ies, PK20, has several modifications of parent fragments
of endogenous peptides. The C-terminal fragment was
modified by substitution of Arg
8 and Arg
9 by lysine resi-
dues, substitutions that are known to leave potency
unchanged [22], and an additional substitution of Ile
12
by Tle (tert-leucine) that should improve the metabolic
stability [25]. The endomorphin-2 pharmacophore, on
the other hand, has been used as the parent opioid
sequence. However, to improve its enzymatic stability
and receptor affinity the N-terminal Tyr
1 has been
replaced by 2,6, dimethyl-tyrosine (Dmt) and Pro
2 has
been replaced by D-lysine. The final structure of PK20
is presented in Figure 1. This paper describes the anti-
nociceptive properties of PK20 in the acute tail flick test
after central (intrathecal, i.t.) application in rats and
after peripheral (intravenous, i.v.) application in mice.
Methods
Measurement of antinociception by intrathecally
administered hybrid PK20 into rats
PK20, the new opioid-neurotensin hybrid peptide was
injected intrathecally into male Wistar rats (weighing
225-250 g) by way of implanted cannulae. Animals
were housed separately and given full access to food
and water. The technique of intrathecal drug adminis-
tration, originally described by Yaksh & Rudy [26], was
used to test the spinal action of the investigated
opioid-neurotensin hybrid peptide, PK20. The analgesic
activity of PK20 was evaluated by using the tail-flick
test (Model 33 Tail Flick Analgesia Meter, USA), in
which the role of the nociceptor agent was fulfilled by
a light beam [27]. The measurement parameters (beam
temperature, the time of rat’s tail exposition on the
irrigation of laser beam) were set properly in order to
avoid the burn of tails.
The effect of action of PK20 was measured at different
doses per rat and within a time frame of 120 minutes (at
5, 15, 30, 60 and 120 minutes after injection). For each
time period three measurements were carried out.
Control responses for each rat in the tail-flick test,
and for each mouse in hot water tail-flick test, were
determined before the injection. Following an intrathecal
injection of saline, morphine, and naltrexone, the
response to PK20 was determined. Regarding naltrex-
one, PK20 was i.t. administered after 10 min interval
after the injection of the opioid blocker.
The tail-flick test was scored as the percent of maxi-
mal possible effect (% MPE) and calculated using the
following equation:
%( ) / ( ) % MPE pdr br co br =− − × 100
where pdr - post drug response, br - baseline
response, co - cut-off value. The cut-off was 7 s for all
experiments (n equals 6).
Measurement of antinociception by intravenously
administered hybrid PK20 into mice
Measurements of antinociception were also carried out
by intravenous administration of PK20 into SWISS
WEBSTER male white mice (weighing 35 - 40 g)
and using the hot water tail-flick test. The hybrid
compound was injected at a dose of 10 and 4 mg/kg.
The effect of PK20 was measured within a period of
120 minutes (at 5, 15, 30, 60 and 120 minutes after
injection). For each time period three measurements
were carried out.
Hot water tail-flick measurements were taken in water
warmed to a temperature of 55.5°C ± 1°C. Latency was
measured as the time that the mice needed to remove
its tail after it was placed into hot water.
Figure 1 Structure of PK20, a hybrid opioid-neurotensin
decapeptide (H-Dmt-D-Lys-Phe-Phe-Lys-Lys-Pro-Phe-Tle-Leu-
OH).
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was mentioned above. However in this case the applied
cut-off was 10 s.
Statistical analysis
All reported data represent the mean % MPE ± SEM.
Significant difference at individual time points between
two groups was determined by Student’s T-test with use
of Statistica® 7.1 software (StatSoft, Tulsa, USA) with
*p < 0.05 and **p < 0.001 being considered significant.
Results
Antinociceptive effects of intrathecally administered PK20
hybrid peptide in tail-flick test
In this experiment, increasing doses of PK20 (0.5-
0.005 nmol/rat) were administered and its analgesic effect
was evaluated within a period of 2 hours by means of the
tail-flick test. In Figure 2 a dose-dependent antinocicep-
tive effect of PK20 is presented. It is shown, that by
increasing doses of the administered peptide, an increas-
ing effect of antinociception was observed only in a lower
doses, up to 0.1 nmol. The higher dose of 0.5 nmol did
not produce a greater effect than 0.1 nmol. Animals
injected with the investigated peptide showed a statisti-
cally significant increase of the % MPE value compared
to the control group. Interestingly, the analgesic effect
induced by PK20 at a dose of 0.1 nmol/rat noted at
5 min after injection was larger than for PK20 at a dose
0 . 5n m o lp e rr a t( a tt h es a m et i m ep o i n t ) ,h o w e v e rt h e r e
was no significant difference observed (P = 0.46676,
t-experiment = 0.764071). Still, in further measurements,
starting from 30 minutes after peptide injection, values of
% MPE were the same as for its lower doses. In Figure 3
the comparison of each dose to PK20 at 0.005 nmol/rat,
is shown. We have also compared two doses of PK20 (0.1
and 0.02 nmol/rat, respectively) with morphine (3 nmol/
rat) as a control group. As is shown in Figure 4C and 4D,
the analgesic strength of the peptide in both doses is
almost similar to this observed for i.t. injected morphine
at a dose of 3 nmol per rat. For a dose of 0.1 nmol of the
opioid-neurotensin hybrid we observed a much greater
analgesic activity than for morphine’s higher concentra-
tion. Interestingly, at 60 min after administration of a
lower dose of PK20 (0.02 nmol/rat), the same value of %
MPE for both morphine and PK20, is obtained.
To evaluate the possible analgesic effect of the neuro-
tensin part of PK20, a μ-opioid receptor blocker, nal-
trexone, which antagonizes the antinociceptive effect,
induced by the opioid subunit in PK20, was used.
In Figure 5 a comparison is presented between the
effect of PK20 at a dose of 0.02 nmol/rat (at which the
analgesic effect is observed) and the analgesic effect of
PK20 (0.02 nmol/rat) administered 10 minutes after a
naltrexone injection (10 μg/rat).
It was observed that, although naltrexone significantly
reduced the analgesic effect induced by PK20, the grow-
ing profile of PK20’s antinociceptive action is still
preserved.
Effects of PK20 hybrid peptide in hot water tail-flick test
after intravenous application in mice
To evaluate PK20’s ability to act after peripheral admin-
istration, and thus to cross the blood-brain barrier
(BBB), we examined the analgesic effect induced by
intravenous application of the peptide at two doses of
4 and 10 mg/kg, respectively.
Figure 2 Effect of increasing doses of hybrid peptide PK20 on analgesia in the rat tail-flick test. The test was performed within 2 h after
the i.t. injection of the compound. % MPE ± SEM of six animals per group. *p < 0.05; **p < 0.001 as compared to saline controls.
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Page 3 of 7Figure 3 Comparison of 0.005 nmol PK20 to other doses of peptide used in the experiment. PK20 was injected intrathecally at doses of
0.02, 0.1 and 0.5 nmol, respectively; % MPE ± SEM of six animals per group.
#p < 0.05;
## p < 0.001 versus 0.02, 0.1 and 0.5 nmol PK20/rat.
Figure 4 The effect of different intrathecal doses of PK20 (0.02, 0.1 nmol) vs. morphine (3 nmol) and with 0.9% NaCl as control. Each
column represents mean ± SEM of 6 animals. *p < 0.05; **p < 0.001 versus saline-injected (A, B); *p < 0.05; **p < 0.001 versus morphine.
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neurotensin hybrid peptide PK20 can exert an analgesic
effect after intravenous injection. Additionally, a growing
time-dependent effect is still observed. When comparing
PK20 to morphine, injected into mice at the same dose
(Figure 6), there is no significant difference between
those two drugs. However, In contrast to Figure 6 when
compared to saline, both administered doses of PK20
demonstrate significant differences (*p < 0.05), which is
shown in Figure 7.
Figure 5 Time-course of the antinociceptive effect of peptide PK20 alone and PK20 after a naltrexone injection. A. analgesic effect of
chimeric compound PK20 injected intrathecally at a dose of 0.02 nmol/rat; B. analgesic effect of PK20 (0.02 nmol), injected 10 min after a
naltrexone (10 μg/rat) injection. % MPE ± SEM of six animals per group. *p < 0.05; **p < 0.001 as compared to rats treated with PK20 (0.02
nmol/rat) alone.
Figure 6 Time-course of the antinociceptive effect of intravenously administered PK20 (4 mg/kg) vs. intraperitoneally injected
morphine (4 mg/kg). Each column represents the mean value ± SEM of 6 - 8 animals. *p < 0.05; **p < 0.001, significantly different from
morphine-injected animals.
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Our in vivo studies have shown that PK20 treatment
results in long-standing time-dependent antinociception
when administered centrally as well as peripherally. This
novel opioid-neurotensin hybrid peptide has a signifi-
cantly intensified analgesic effect, when compared to sal-
ine and morphine. The improved analgesia mediated by
this peptide suggests a possible plasma stability and
implies a delayed enzymatic degradation (data not pub-
lished). Intrathecal injection of PK20 at a dose of 0.02
nmol/rat exerts a similar analgesic action to that
observed for morphine at 3 nmol/rat, indicating a very
high antinociceptive potency of the investigated peptide.
Interestingly, by increasing the concentration of the
administered compound (range between 0.1-0.5 nmol/
rat) the antinociceptive effect at 0.5 nmol/rat starts from
al o w e rv a l u et h a na t0 . 1n m o l / r a td u r i n gt h ef i r s t
15 minutes after injection, which might be interpreted
as a short delay in response to nociceptive stimuli.
Naltrexone, injected 10 min before the compound,
effectively attenuated the antinociceptive action pro-
duced by the hybrid peptide. However, a slight and still
time-dependent growing profile of analgesic effect of
PK20 is still preserved. These findings indicate that nal-
t r e x o n eo n l yp a r t i a l l yi n h i bited the antinociceptive
action of PK20, suggesting that also the neurotensin
fragment is involved in analgesia. The analgesic response
induced by PK20 is mediated not only through activa-
tion of the opioid pathway, but also through action at
neurotensin receptors.
Our study also indicates the ability of PK20 to cross
the highly selective blood-brain barrier, which was
examined by its intravenous administration into mice
(hot water tail-flick test). Since only a few neurotensin
analogs were reported to cross the BBB, like a com-
pound from the Eisai group [23] or NT66L and NT69L
[19,28], PK20 seems to be a very interesting novel pain
relieving drug.
Neurotensin as well as opioids exert analgesia. Opioids
drugs block pain signals by interacting especially with
mu-opioid receptors, whereas NT or its analogs act
independently of the opioid pathways. Therefore, by
combining these two elements, the antinociceptive effect
might be obtained either by the opioid or neurotensin
part alone, or by synergy of two interacting parts, thus
acting more efficiently than in case of separate adminis-
tration of each of them.
Having in mind the fact that chronic administration of
opiates generally produce tolerance [29,30] and depen-
dence, which are highly undesirable effects, the creation
of novel compounds such as this hybrid may have an
influence on the reduction of these side-effects and
Figure 7 Time-course of the antinociceptive effect of PK20 after i.v. administration (4 mg/kg and 10 mg/kg, respectively) vs.
intravenously administered of 0.9% NaCl solution. Each column represents mean ± SEM of 6 - 8 animals. *p < 0.05; **p < 0.001, significantly
different from saline-injected mice.
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ficiently relief pain states.
The comparative studies on tolerance development
after multiple application of PK20 and morphine are in
progress.
Conclusions
The opioid-neurotensin hybrid analogue PK20, in which
opioid and neurotensin pharmacophores partially over-
lap, expresses high antinociceptive tail-flick effects after
central as well as peripheral application.
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